We have utilized the estrogen receptor (ER)-positive human breast carcinoma cell line, T47D, to determine the role of ER in regulating cell proliferation, the level of expression of p53 and the state of phosphorylation of retinoblastoma protein (pRB) by 17 b-estradiol (E 2 ) and antiestrogens. T47D cells cultured for 7 days proliferated rapidly expressing maximal levels of p53 in medium containing 5% fetal bovine (whole) serum. Exogenously added E 2 had no eect on either of the above parameters. The antiestrogen, ICI 164,384 (ICI, 1 mM), decreased cell number and p53 level to nearly 20% of the control. Comparatively, a treatment of the cells with 100 nM 4OH-tamoxifen (OHT) decreased cell number to 40% of the control without a concomitant decrease in the p53 levels suggesting a dierential ability of these antiestrogens to regulate p53 levels in cells cultured in whole serum. When cells were cultured in medium containing serum depleted of endogenous steroids (charcoal stripped serum), cell number and p53 levels declined. Treatment with exogenous E 2 (1 nM) increased cell proliferation, p53 expression and phosphorylation of pRB. The antiestrogens ICI and OHT blocked these E 2 eects, demonstrating a direct antagonism of ER by ICI and OHT. These results indicate an ER-mediated mechanism for coordinate expression of p53 and hyperphosphorylation of pRB during E 2 -induced proliferation of T47D cells.
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Keywords: breast cancer; tumor suppressors; p53; retinoblastoma; estrogens; antiestrogens Bene®ts of adjuvant tamoxifen (TAM) chemotherapy for treatment of early hormone-dependent breast cancers have been widely demonstrated. The TAM eects are most evident when primary tumors are diagnosed as ER-positive raising the possibility that ER might mediate the protective eects of TAM. A number of studies utilizing ER-positive cell lines also indicate that ER mediates protective eects of antiestrogens (Bardon et al., 1987; Thompson et al., 1989; Levenson and Jordan, 1994; Kushner et al., 1990) . However, the continued expression of ER in patients with tumor progression indicates that resistance can occur without receptor loss (Encarnacion et al., 1993; Osborne et al., 1991) . It is, thus, important to determine why, in cases where a functional ER is present, breast cancer cells continue to proliferate and progress to a resistant state in spite of antiestrogen therapy.
Incidence and progression of the cancerous state are signi®cantly in¯uenced by deregulation of oncogenes or inactivation of tumor suppressors. Although steroid hormones have been shown to regulate the levels of protooncogenes (Schuchard et al., 1993) , less is understood concerning their eects on the expression of tumor suppressors such as p53. Mutations of the p53 gene are by far the most common markers for cancer (Harris, 1993) and abnormalities in p53 gene loci indicate that it plays a crucial role in breast cancer etiology (Nigro et al., 1989; Runnebaum et al., 1991; Cale et al., 1994; Saitoh et al., 1994) . While mutational status of p53 is a crucial factor in determining cell fate, the role of p53 expression and regulation in cancer etiology remains unclear. How it is normally regulated and how agents used in the treatment of breast cancer, such as antiestrogens, aect its expression is, however, unknown.
The T47D breast cancer cell line is ER-and progesterone receptor (PR)-positive and expresses p53 with a missense mutation at codon 194 converting leucine to phenylalanine in the protein (Nigro et al., 1989) . This cell line oers an experimental model to study eects of estrogens and antiestrogens in breast cancer cells with a mutated p53. We had previously shown that E 2 treatment was sucient to maintain high levels of p53 in T47D cells (Hurd et al., 1995) . In the present study, we demonstrate that E 2 -induced p53 accumulation in T47D cells correlates with cell proliferation and pRB phosphorylation. The antiestrogens, ICI and OHT block these eects, indicating an ER-mediated mechanism for the coordinated regulation of these two paradigm tumor suppressors in E 2 -dependent proliferation of T47D breast cancer cells.
Regulation of p53 by antiestrogens depends on the composition of the cell culture medium
We compared the eects of E 2 and the antiestrogens on p53 levels from cells cultured in either whole serum (containing endogenous E 2 ) or in stripped serum supplemented with a known concentration of E 2 (1 nM). An equal number of cells were plated for 2 days in whole serum and were then maintained for 7 days in whole serum plus E 2 , OHT, ICI or TAM. Alternatively, cells were cultured in medium containing stripped serum supplemented with E 2 plus the antiestrogens at concentrations as indicated in Figure 1 . In the cells grown in whole serum, high levels of p53 were detected by Western analysis in the control group or in those where E 2 was added exogenously. The level of p53 decreased signi®cantly in cells treated with ICI whereas OHT and TAM were less eective in decreasing p53 levels. The p53 levels were depleted in cells cultured in stripped serum. Addition of E 2 restored p53 levels demonstrating that the eects of stripped serum can be reversed by E 2 . ICI and OHT blocked this E 2 eect in contrast to TAM which did not.
The ability of the antiestrogens to complex with ER correlated with their eects on p53. E 2 , ICI and OHT but not TAM eectively competed for the estrogen binding sites (not shown). The relative inability of TAM to compete for E 2 binding suggested that 1 nM E 2 is sucient to bind and activate ER and maintain the levels of p53 even in the presence of a 1000-fold molar excess of this low anity antiestrogen. These observations suggest that OHT and ICI act as potent antiestrogens blocking E 2 -induced expression of p53. The relative inability of OHT to reduce the levels of p53 in cells cultured in whole serum is consistent with its status as a less potent antiestrogen than ICI. The results also suggest that factors in whole serum (but not in depleted serum) are able to override OHT antagonism of ER with respect to p53 expression in this cell line, whereas ICI, a more potent antiestrogen blocks signals originating from factors in whole serum that require ER mediation for p53 expression.
Cell proliferation correlates with p53 expression
We next assessed the eects of E 2 and the antiestrogens on T47D cell proliferation in order to correlate this with p53 expression. Cells were treated as above, and proliferation was determined by cell counting (Figure 2 ). When cells were cultured in whole serum or stripped serum supplemented with E 2 , all the antiestrogens had an inhibitory eect on proliferation with the exception of TAM which was ineective in cells grown in stripped serum supplemented with E 2 (ICI4OHT4TAM). This eect also correlated with the ability of the antiestrogens to compete with E 2 for binding to ER. E 2 treatment of cells cultured in whole serum had a marginal eect on proliferation. As Figure 2 Eect of E 2 and antiestrogens on T47D cell proliferation in cells cultured in whole serum versus stripped serum supplemented with estrogen. Cells in triplicate were plated in 12-well growth plates (30 000 cells/well) and cultured for 2 days in whole serum and then treated with 1 nM E 2 , 100 nM 4 OH-tamoxifen (OHT), 1 mM ICI 164,384 (ICI) or 1 mM tamoxifen (TAM) (Whole; left panel) or cultured in stripped serum supplemented with 1 nM E 2 plus the same concentration of antiestrogens (Stripped). Cells were cultured for 7 days. Fresh media and ligands were replaced at 2 day intervals. Cell number was determined by Coulter counter as described previously (Kodali et al., 1994) . Error bars represent standard deviations of triplicate cell counts. Absence of error bars indicates a deviation less than the ability of the graphics program to discern
Whole Figure 1 Dierential eect of ICI 164,384 and 4 OH-tamoxifen on p53 levels in T47D cells cultured in whole serum versus stripped serum supplemented with estrogen. T47D cells were obtained from American Type Culture Collection and were maintained as previously described (Kodali et al., 1994) . Cells were cultured for 2 days in whole serum prior to treatment with concentrations of E 2 , 4 OH-tamoxifen (OHT), ICI 164,384 (ICI) or tamoxifen (TAM) as indicated. Cells were either maintained in whole serum plus the antiestrogens (Whole) or changed to media containing stripped serum supplemented with 1 nM E 2 plus the antiestrogens (Stripped). Fresh media and ligands were replaced at 2 day intervals and the cells were cultured for 7 days under these conditions. Protein extracts were prepared and the quantity of p53 determined by SDS ± PAGE and Western analysis as described previously (Hurd et al., 1995) . For this experiment, a 1:500 dilution of primary antibody, anti-p53 monoclonal antibody (Transduction Laboratories) was used presented in Figure 1 , addition of E 2 to cells cultured in whole serum also had no detectable eects on p53 levels, which were already maximal. ICI and OHT both inhibited cell proliferation but ICI was more eective in down regulating p53. Culturing in stripped serum reduced the cell population by 46% (compare controls in stripped versus whole serum) suggesting that charcoal treatment removes factor(s) required for maximal T47D cell proliferation. E 2 addition increased the cell count by 26%, consistent with the increased p53 expression during the E 2 -induced proliferative state. ICI and OHT, which countered the E 2 eect on p53 expression, also reduced the cell number signi®cantly below the control. These data are consistent with an ERmediated upregulation of p53 during cell proliferation. Interestingly, OHT appeared more eective in reducing proliferation of cells grown in whole serum than in decreasing the levels of p53.
Estrogen treatment of T47D and MCF-7 cells causes coordinated up-regulation of p53 and hyperphosphorylation of pRB
In cycling cells, pRB acts as a switch controlling the G 1 /S transition of the cell cycle (Weinberg, 1995) . As cells progress through G 1 , the suppressor function of pRB is inactivated by sequential phosphorylation at cyclin dependent kinase (cdk) consensus target sites (Mihara et al., 1989; DeCaprio et al., 1992; Mittnatch et al., 1994; Knudsen and Wang, 1996) which can be detected as an upshift during SDS ± PAGE (Mihara et al., 1989; DeCaprio et al., 1992) . In the E 2 -responsive breast cancer cell line MCF-7, E 2 treatment has been shown to be sucient to induce slower mobility hyperphosphorylated form(s) of pRB (ppRB) during SDS ± PAGE (Foster and Wimalasena, 1996) . Furthermore, an antiestrogen (ICI 182,780) has been shown to cause accumulation of the hypophosphorylated pRB (Watts et al., 1995) . Thus, we also analysed E 2 -induced phosphorylation of pRB in MCF-7 cells as a positive control for phosphorylation of pRB following E 2 treatment of T47D cells.
To determine the phase of the cell cycle in which E 2 stimulates expression of p53, we analysed the expression of p53 and the phosphorylation state of pRB in the same samples of protein extracts. Cells were cultured for 6 days in stripped serum to withdraw them from E 2 stimulus and then treated with 1 nM E 2 for 0 ± 48 h. E 2 treatment during this period caused (a) an increase in the p53 level which was detectable at 6 h, reaching 70% the level seen in the control (not shown) by 24 h and (b) accumulation of the ppRB in both cell types (Figure 3) . The levels of p53 and ppRB were maximal at a 24 h treatment of T47D cells with E 2 . Hyperphosphorylation of pRB occurred abruptly between 12 and 24 h in T47D cells, whereas in MCF-7 cells, it occurred earlier and more gradually. Furthermore, medium containing stripped serum plus E 2 was both necessary and sucient to observe hyperphosphorylation of pRB in T47D cells. In serum-free medium supplemented with E 2 , pRB was not phosphorylated (data not shown). A decrease in the levels of p53 was observed after 48 h of E 2 treatment and also an apparent reversal of ppRB to pRB although ppRB was still detectable (Figure 3 ). This observation may be related to cells reentering the G 1 phase of the cycle in which pRB is dephosphorylated (Mihara et al., 1989; DeCaprio et al., 1992) . These results show that E 2 treatment of T47D cells cultured in stripped serum is sucient to induce hyperphosphorylation of pRB and that E 2 is capable of stimulating this event which is highly correlated with G 1 to S phase transition of the cell cycle. Under similar culturing and treatment conditions the kinetics of phosphorylation of pRB were dierent in MCF-7 and T47D cells. Phosphorylation of pRB is positively regulated by cdk activity and negatively regulated by cdk inhibitors such as p21 and p27. These positive and negative regulators of phosphorylation of pRB may be dierentially regulated in the two cell lines.
ICI and OHT, but not TAM block E 2 -induced hyperphosphorylation of pRB and up-regulation of p53
We next analysed the ability of antiestrogens to block E 2 -induced accumulation of p53 and hyperphosphorylation of pRB (Figure 4 ). T47D cells were cultured for 6 days in stripped serum and then treated with 1 nM E 2 for 24 h in the absence and presence of ICI, TAM or OHT. As expected, E 2 treatment caused hyperphosphorylation of pRB and raised the p53 level. The antiestrogens ICI and OHT, which also compete for ER binding in T47D cells, blocked the E 2 -induced p53 response and hyperphosphorylation of pRB. In contrast, TAM was completely ineective. These data indicate that an E 2 -induced p53 and phosphorylation of pRB are coordinated events mediated by ER.
According to the current model explaining the mode of p53-mediated G 1 cell cycle arrest (Sherr, 1994) , our results present an apparent paradox. The predomi- Cells were passaged into media containing whole fetal bovine serum for 2 days and then withdrawn from E 2 stimuli by culturing them for 6 days in media containing stripped serum. The cells were then treated with 1 nM E 2 for time periods from 1 ± 48 h as indicated. Lane represented as 0 was not treated with E 2 . Protein extracts were prepared and the quantities of p53, hypophosphorylated (pRB) and hyperphosphorylated retinoblastoma protein (ppRB) were determined by SDS ± PAGE (7%) and Western blot analysis as described previously (Hurd et al., 1995) . For immunodetection of pRB, a 1:500 dilution of puri®ed anti-human retinoblastoma, clone G3-245 (Pharmingen) was employed nance of hypophosphorylated pRB in T47D cells prior to E 2 treatment suggests that they are arrested in G 1 phase and progress into S phase with a concomitant increase in p53 expression in response to E 2 . Increased expression of p53 which transactivates p21
Waf1/Cip1 (Blagosklonny et al., 1995; Dulic et al., 1994; El-Deiry et al., 1993; Kastan et al., 1991; Xiong et al., 1993; Wa®k et al., 1994) should cause an inhibition of cdks and result in dephosphorylated pRB. However, we have observed hyperphosphorylation of pRB concomitant with increased p53 expression upon E 2 stimulus of the cells and no correlation between the levels of p53 and p21 after treatment of T47D cells with E 2 or the antiestrogens (data not shown). Thus increased expression of p53 in the T47D cell line in response to E 2 does not activate the p21 Waf1/Cip1 pathway sucient to inhibit pRB phosphorylation.
The observed concomitant E 2 -induced accumulation of p53, which may be non-functional in T47D cells, suggests that E 2 -induced cell cycle progression is checked by this tumor suppressor in cells containing wild type p53 possibly by the p21 Waf1/Cip1 pathway. Under non-pathological conditions, E 2 -dependent mitosis in breast cells may be checked by an initial activation of p53 function. A mutant form of p53, as in T47D cells, may be unable to mediate these controls on E 2 -induced cell proliferation and thus E 2 may accelerate tumor progression under these circumstances via default of p53-mediated cell cycle arrest, DNA repair and/or apoptosis.
Treatments which enhance the expression of wild type p53 appear to be clinically eective due to p53-mediated apoptosis of cancer cells (Lowe et al., 1994) . In ER-positive breast cancers with a wild type p53, antiestrogen treatment could result in breast cancer cells resistant to cytotoxic or radiation therapy due to insucient levels of p53 (Guillot et al., 1996) . Antiestrogen treatment in cases where mutant p53 is present may well be indicated since as we have shown in this paper with the T47D cell line, antiestrogens can block E 2 -induced hyperphosphorylation of pRB and reduce cell proliferation even when p53 appears to be non-functional. cytotoxic, or immune therapy. Figure 4 Antiestrogens block estrogen-induced p53 expression and hyperphosphorylation of pRB. Cells were passaged into media containing whole serum for 2 days and then withdrawn from E 2 stimuli by culturing them for 6 days in media containing stripped serum. The cells were then treated with E 2 alone or combined with concentrations of ICI 164,384 (ICI), tamoxifen (TAM) or 4 OH-tamoxifen (OHT) as indicated for 24 h. The lane marked C Whole represents cells cultured in whole serum in the absence of exogenous ligands. All other lanes were cultured in stripped serum for 6 days prior to addition of ligands. Protein extracts were prepared and the quantities of hypophosphorylated (pRB), hyperphosphorylated retinoblastoma (ppRB) and p53 were analysed by SDS ± PAGE and Western blot
